MX2020013306A - Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos. - Google Patents

Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos.

Info

Publication number
MX2020013306A
MX2020013306A MX2020013306A MX2020013306A MX2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A MX 2020013306 A MX2020013306 A MX 2020013306A
Authority
MX
Mexico
Prior art keywords
intensive care
post
halogen compounds
prevention
treatment
Prior art date
Application number
MX2020013306A
Other languages
English (en)
Spanish (es)
Inventor
Mark B Roth
Michael L Morrison
Akiko Iwata
Stephen A Hill
John W Langston
Michael Andrew Insko
Original Assignee
Faraday Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faraday Pharmaceuticals Inc filed Critical Faraday Pharmaceuticals Inc
Publication of MX2020013306A publication Critical patent/MX2020013306A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2020013306A 2018-06-08 2019-06-07 Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos. MX2020013306A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862682574P 2018-06-08 2018-06-08
US201862730927P 2018-09-13 2018-09-13
US201862730945P 2018-09-13 2018-09-13
PCT/US2019/036154 WO2019237065A1 (en) 2018-06-08 2019-06-07 Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome

Publications (1)

Publication Number Publication Date
MX2020013306A true MX2020013306A (es) 2021-05-12

Family

ID=68770655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013306A MX2020013306A (es) 2018-06-08 2019-06-07 Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos.

Country Status (10)

Country Link
US (1) US20210252047A1 (cg-RX-API-DMAC7.html)
EP (1) EP3801565A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021527130A (cg-RX-API-DMAC7.html)
KR (1) KR20210018898A (cg-RX-API-DMAC7.html)
CN (1) CN112469422A (cg-RX-API-DMAC7.html)
AU (1) AU2019282820A1 (cg-RX-API-DMAC7.html)
CA (1) CA3102792A1 (cg-RX-API-DMAC7.html)
IL (1) IL279221A (cg-RX-API-DMAC7.html)
MX (1) MX2020013306A (cg-RX-API-DMAC7.html)
WO (1) WO2019237065A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120458A1 (en) 2014-02-10 2015-08-13 Fred Hutchinson Cancer Research Center Halogen treatment of heart attack and ischemic injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248335B1 (en) * 1997-10-29 2001-06-19 Symbollon Corporation Stabilized oral pharmaceutical composition containing iodide and iodate and method
CZ295765B6 (cs) * 1998-07-29 2005-10-12 Apa - Praha, S.R.O. Léčebný přípravek s virucidním účinkem
GB0525504D0 (en) * 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
WO2015120458A1 (en) * 2014-02-10 2015-08-13 Fred Hutchinson Cancer Research Center Halogen treatment of heart attack and ischemic injury

Also Published As

Publication number Publication date
IL279221A (en) 2021-01-31
US20210252047A1 (en) 2021-08-19
CN112469422A (zh) 2021-03-09
WO2019237065A1 (en) 2019-12-12
JP2021527130A (ja) 2021-10-11
EP3801565A4 (en) 2022-04-06
EP3801565A1 (en) 2021-04-14
CA3102792A1 (en) 2019-12-12
KR20210018898A (ko) 2021-02-18
AU2019282820A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
IL285782A (en) Compounds, compositions, and methods for the treatment of disease
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
IL276398A (en) Combined treatment for mastocytosis
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MX387115B (es) Métodos para tratar la influenza.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2019009753A (es) Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos.
HK1253734A1 (zh) 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1,4]恶嗪磺酰胺和相关化合物
SI3700529T1 (sl) Nova kombinacija zdravilnih učinkovin za zdravljenje progresivnih fibroznih intersticijskih pljučnih bolezni (PF-ILD)
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
ZA201705874B (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
WO2016004413A3 (en) Gls1 inhibitors for treating disease
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
PH12020551179A1 (en) Methods for treating mitochondrial disorder
EP4000609A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
KR102177130B9 (ko) 근육 질환 및 신경근육 질환 예방, 치료 또는 진단을 위한 miR-18b의 용도
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
EP3946433A4 (en) COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OF FABRY DISEASE
MX2020013100A (es) Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.